Given their ability to prime and expand antigen‐specific CD4+ and CD8+ T‐cell responses, DCs are crucial players in the so‐called “cancer‐immunity cycle,” a series of stepwise events that generate anticancer immune responses [35]. Here, CD8A is linked to cancer.